The immunogenicity and safety of vaccination with purified vero cell rabies vaccine (PVRV) in China under a 2-1-1 regimen

Human Vaccines

Volumn 7, Issue 2, 2011, Pages 220-224

  Liu, Huazhang ^a   Huang, Guihua ^a   Tang, Qing ^b   Li, Jia ^c   Cao, Shouchun ^c   Fu, Chuanxi ^a   Cao, Qing ^a   Liu, Beiyan ^a   Pan, Huai ^a   Wang, Ming ^a  

^a GUANGZHOU CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^b CHINESE CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

^c NATIONAL INSTITUTE FOR THE CONTROL OF PHARMACEUTICAL AND BIOLOGICAL PRODUCTS   (China)

Author keywords

Rabies vaccine; Vero cell; Zagreb regimen

Indexed keywords

NEUTRALIZING ANTIBODY; PURIFIED VERO CELL RABIES VACCINE; RABIES VACCINE; SPEEDA; UNCLASSIFIED DRUG;

ADULT; ARTICLE; BLOOD SAMPLING; CHINA; CLINICAL PROTOCOL; CONTROLLED STUDY; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG MONITORING; DRUG POTENCY; DRUG SAFETY; DRUG TOLERABILITY; EDEMA; ERYTHEMA; FEMALE; HUMAN; HUMAN EXPERIMENT; IMMUNIZATION; IMMUNOGENICITY; INJECTION SITE INDURATION; MALAISE; MALE; MYALGIA; NORMAL HUMAN; PAIN; PHASE 4 CLINICAL TRIAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; SEROLOGY; SINGLE BLIND PROCEDURE; SOMNOLENCE; VACCINATION;

ADULT; ANIMALS; ANTIBODIES, VIRAL; CERCOPITHECUS AETHIOPS; CHINA; FEMALE; HUMANS; IMMUNIZATION PROGRAMS; MALE; MIDDLE AGED; RABIES VACCINES; VACCINATION; VERO CELLS;

EID: 79952483582     PISSN: 15548600     EISSN: 15548619     Source Type: Journal    
DOI: 10.4161/hv.7.2.14003     Document Type: Article

References (15)

1. Warrell D, Gutiérrez JM. Rabies and envenomings: a neglected public health issue: report of a Consultative Meeting 2007.
2. Ministry of Health, People's Republic of China. Available at: http://www.moh.gov.cn.
3. WHO expert consultation on rabies. First report. WHO Tech Rep Ser 931. Geneva: WHO 2005.
4. China Rabies Control Situation. China Animal Husbandry and Veterinary Medicine 2009; 36:144-6; In Editor.
5. WHO Expert Committee on Rabies. Guide for post-exposure treatment. Eighth report. WHO technical report 824. Geneva Switzerland: World Health Organization 1992.
6. Lang J, Simanjuntak GH, Soerjosembodo S, Koesharyono C. Suppressant effect of human or equine rabies immunoglobulins on the immunogenicity of post-exposure rabies vaccination under the 2-1-1 regimen: a field trial in Indonesia. MAS054 Clinical Investigator Group. Bull World Health Organ 1998; 76:491-5. (Pubitemid 29014264)
7. Colnot F, Sureau P, Alexandre JL, Arnaudo JP, Hesse JY, Jeanmaire H. [Post-exposure antirabies vaccination. Early serological response to vaccine cultivated on VERO cells using a reduced 2-1-1 schedule]. Presse Med 1994; 23:1609-12.
8. Chutivongse S, Wilde H, Fishbein DB, Baer GM, Hemachudha T. One-year study of the 2-1-1 intramuscular postexposure rabies vaccine regimen in 100 severely exposed Thai patients using rabies immune globulin and Vero cell rabies vaccine. Vaccine 1991; 9:573-6.
9. Huazhuang L, Guihua H, Qing C, Huai P. Adverse reaction and immune effect of domestic adjuvant-free rabies vaccine prepared with vero cells. Ch J Biologicals 2008; 21:327-8.
10. Li Z, Jun G, Jianying H, Zhumu B, Deming Y. Safety and immune effect of adjuvant-free rabies vaccine. Ch J Biologicals 2006; 19:206-7.
11. Han Si ZGYH. Rabies trend in China (1990-2007) and post-exposure prophylaxis in the Guangdong province. Bmc Infect Dis 2008; 8.
12. World survey of rabies No. 34 for the year 1998. Geneva: WHO 1999. WHO document CSR/APH/99.6 1999.
13. Zalan E, Wilson C, Pukitis D. A microtest for the quantitation of rabies virus neutralizing antibodies. J Biol Stand 1979; 7:213-20. (Pubitemid 9248692)
14. Chinnese Academy Of Social Sciences. Http://www.cass.net.cn/show-news. asp?ID = 85570.
15. Rupprecht CE, Briggs D, Brown CM, Franka R, Katz SL, Kerr HD, et al. Eds. Use of a reduced (4-dose) vaccine schedule for postexposure prophylaxis to prevent human rabies: recommendations of the advisory committee on immunization practices: Centers for Disease Control and Prevention (CDC) MMWR Recomm Rep 2010; 59:1-9.